1. FRI0069 Neutralization of IL6 by Sirukumab (SIR) Inhibits Inflammation and Cellular Stress in a Human Vascular Surrogate System of Atherosclerosis. (9th June 2015) Authors: Feaver, R.; Collado, S.; Hoang, S.; Berzin, E.; Armstrong, A.; Gardner, D.; Liu, H.; Mackey, A.; Manka, D.; Shealy, D.; Blackman, B. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0042 Preclinical Characterization of Sirukumab, a Human Monoclonal Antibody that Targets Human Interleukin-6 Signaling. (9th June 2015) Authors: Gardner, D.; Lacy, E.; Wu, S.; Shealy, D. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗